Spero Therapeutics (SPRO) Receivables - Other (2016 - 2026)

Spero Therapeutics (SPRO) has reported Receivables - Other for 11 consecutive years, with -$19000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 100.77% year-over-year to -$19000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.6 million (down 246.75% YoY), and the FY2025 full-year result was -$3.1 million, down 199.09% from the prior year.
• Receivables - Other retreated to -$19000.0 in Q2 2026 per SPRO's latest filing, from $44000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $5.0 million in Q1 2024 and bottomed at -$2.4 million in Q1 2025.
• Historically, Receivables - Other has averaged $1.3 million across 5 years, with a median of $1.6 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other jumped 244.74% in 2022, then plunged 1202.29% in 2023.
• Over 5 years, Receivables - Other stood at $131000.0 in 2022, then slumped by 1202.29% to -$1.4 million in 2023, then jumped by 126.94% to $389000.0 in 2024, then plunged by 501.8% to -$1.6 million in 2025, then soared by 98.78% to -$19000.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered -$19000.0, $44000.0, and -$1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.